Nàdarra Health has opened its equity crowdfunding campaign through Birchal, targeting up to $1.2 million from public investors to fund its next phase of commercial and clinical development.
Shares are priced at $5.60 each — well above what previous Birchal raises by medicinal cannabis companies have achieved, and a valuation ASX-listed peers would envy — with the company's pre-raise valuation set at $8 million.
A fully subscribed raise would result in the issuance of 214,285 new shares, giving investors a combined stake of up to 13% of the company. The offer is scheduled to close on July 10.
As of Thursday, Nàdarra had collected $86,548 from 66 investors, putting it at 86% of its $100,000 minimum threshold.
The company, founded in 2023, has already brought two flower products to market — Green Jeannie and Indica Jones — and is preparing to release its first edible product, C3 Harmony, later this month.
Nàdarra generated $30,884 in revenue during FY24 and $66,053 across the ten months to April 2025, a 139% jump on the prior full-year figure.
Capital raised through the offer will go toward launching its edible product line, expanding the company's Melbourne warehouse and distribution operations, and funding prescriber education. A portion will also be directed at international expansion and R&D work on a new pain-relief device, which the company intends to advance through clinical trials.
Nàdarra is currently wholly owned by its three co-founders: David Hartley, Neil Bates and Simon Bisso.
